(New York) – Akin advised Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager for the BioPharma Credit funds, and the BioPharma Credit Funds in connection with an up to CHF 250 million senior secured term loan to Idorsia Ltd, with the first tranche of CHF 105 million funded at closing. Idorsia Ltd is a leading, commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, focused on discovering...
Continue Reading
Sign up for FREE to read the full article and access 131K+ alternative investment headlines.